These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1134 related items for PubMed ID: 31126769

  • 1. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.
    Caradu C, Lakhlifi E, Colacchio EC, Midy D, Bérard X, Poirier M, Ducasse E.
    J Vasc Surg; 2019 Sep; 70(3):981-995.e10. PubMed ID: 31126769
    [Abstract] [Full Text] [Related]

  • 2. Drug-coated balloon versus plain old balloon angioplasty in femoropopliteal disease: An updated meta-analysis of randomized controlled trials.
    Anantha-Narayanan M, Shah SM, Jelani QU, Garcia S, Ionescu C, Regan C, Mena-Hurtado C.
    Catheter Cardiovasc Interv; 2019 Jul 01; 94(1):139-148. PubMed ID: 30838719
    [Abstract] [Full Text] [Related]

  • 3. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
    Tepe G, Schroeder H, Albrecht T, Reimer P, Diehm N, Baeriswyl JL, Brechtel K, Speck U, Zeller T.
    J Endovasc Ther; 2020 Apr 01; 27(2):276-286. PubMed ID: 32096451
    [Abstract] [Full Text] [Related]

  • 4. Comparison of drug-coated balloon angioplasty versus uncoated balloon angioplasty in treatment of total occlusions with severe femoropopliteal lesions: An additional analysis from the AcoArt I study.
    Sun G, Liu J, Jia S, Zhang J, Zhuang B, Jia X, Fu W, Wu D, Wang F, Zhao Y, Guo P, Bi W, Wang S, Guo W, AcoArt I Trial Investigators.
    Vascular; 2021 Jun 01; 29(3):340-349. PubMed ID: 32903168
    [Abstract] [Full Text] [Related]

  • 5. Network Meta-Analysis of All Available Regimens Based on Drug-Coated Balloon Angioplasty and Laser Atherectomy for Femoropopliteal In-Stent Restenosis.
    Yu C, Tang W, Ren T, Chen Q, Lu R, Gao Y.
    J Endovasc Ther; 2024 Jun 01; 31(3):390-399. PubMed ID: 36189843
    [Abstract] [Full Text] [Related]

  • 6. Systematic Review and Meta-analysis of Randomized Controlled Trials of Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Arteries: Role of Paclitaxel Dose and Bioavailability.
    Katsanos K, Spiliopoulos S, Paraskevopoulos I, Diamantopoulos A, Karnabatidis D.
    J Endovasc Ther; 2016 Apr 01; 23(2):356-70. PubMed ID: 26823485
    [Abstract] [Full Text] [Related]

  • 7. Drug-Coated Balloons for Complex Femoropopliteal Lesions: 2-Year Results of a Real-World Registry.
    Schmidt A, Piorkowski M, Görner H, Steiner S, Bausback Y, Scheinert S, Banning-Eichenseer U, Staab H, Branzan D, Varcoe RL, Scheinert D.
    JACC Cardiovasc Interv; 2016 Apr 11; 9(7):715-24. PubMed ID: 27056311
    [Abstract] [Full Text] [Related]

  • 8. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
    Steiner S, Willfort-Ehringer A, Sievert H, Geist V, Lichtenberg M, Del Giudice C, Sauguet A, Diaz-Cartelle J, Marx C, Ströbel A, Schult I, Scheinert D, RANGER SFA Investigators.
    JACC Cardiovasc Interv; 2018 May 28; 11(10):934-941. PubMed ID: 29730375
    [Abstract] [Full Text] [Related]

  • 9. Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease.
    Herten M, Torsello GB, Schönefeld E, Stahlhoff S.
    Vasc Health Risk Manag; 2016 May 28; 12():341-56. PubMed ID: 27621646
    [Abstract] [Full Text] [Related]

  • 10. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
    Kinstner CM, Lammer J, Willfort-Ehringer A, Matzek W, Gschwandtner M, Javor D, Funovics M, Schoder M, Koppensteiner R, Loewe C, Ristl R, Wolf F.
    JACC Cardiovasc Interv; 2016 Jul 11; 9(13):1386-92. PubMed ID: 27388828
    [Abstract] [Full Text] [Related]

  • 11. Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment.
    Bausback Y, Willfort-Ehringer A, Sievert H, Geist V, Lichtenberg M, Del Giudice C, Sauguet A, Diaz-Cartelle J, Marx C, Ströbel A, Schult I, Scheinert D, RANGER SFA Investigators.
    J Endovasc Ther; 2017 Aug 11; 24(4):459-467. PubMed ID: 28558502
    [Abstract] [Full Text] [Related]

  • 12. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.
    Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, Tepe G, Naisbitt S, Rosenfield K.
    JACC Cardiovasc Interv; 2014 Jan 11; 7(1):10-9. PubMed ID: 24456716
    [Abstract] [Full Text] [Related]

  • 13. Network meta-analysis of drug-coated balloon angioplasty versus primary nitinol stenting for femoropopliteal atherosclerotic disease.
    Abdoli S, Mert M, Lee WM, Ochoa CJ, Katz SG.
    J Vasc Surg; 2021 May 11; 73(5):1802-1810.e4. PubMed ID: 33249205
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of Mortality Following Paclitaxel Drug-Coated Balloon Angioplasty of Femoropopliteal Lesions in the Real World.
    Böhme T, Noory E, Beschorner U, Jacques B, Bürgelin K, Macharzina R, Gebauer E, Cheung F, Lechner P, Nührenberg T, Zeller T.
    JACC Cardiovasc Interv; 2020 Sep 14; 13(17):2052-2061. PubMed ID: 32593696
    [Abstract] [Full Text] [Related]

  • 15. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
    Scheinert D, Schmidt A, Zeller T, Müller-Hülsbeck S, Sixt S, Schröder H, Weiss N, Ketelsen D, Ricke J, Steiner S, Rosenfield K.
    J Endovasc Ther; 2016 Jun 14; 23(3):409-16. PubMed ID: 27117972
    [Abstract] [Full Text] [Related]

  • 16. Drug-Coated Balloon Versus Plain Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Giacoppo D, Cassese S, Harada Y, Colleran R, Michel J, Fusaro M, Kastrati A, Byrne RA.
    JACC Cardiovasc Interv; 2016 Aug 22; 9(16):1731-42. PubMed ID: 27539695
    [Abstract] [Full Text] [Related]

  • 17. Drug-Coated Balloon Angioplasty for Femoropopliteal In-Stent Restenosis.
    Cassese S, Wolf F, Ingwersen M, Kinstner CM, Fusaro M, Ndrepepa G, Ibrahim T, Ott I, Lammer J, Krankenberg H, Fusaro M.
    Circ Cardiovasc Interv; 2018 Dec 22; 11(12):e007055. PubMed ID: 30562083
    [Abstract] [Full Text] [Related]

  • 18. The 24-Month Results of the Lutonix Global SFA Registry: Worldwide Experience With Lutonix Drug-Coated Balloon.
    Thieme M, Von Bilderling P, Paetzel C, Karnabatidis D, Perez Delgado J, Lichtenberg M, Lutonix Global SFA Registry Investigators.
    JACC Cardiovasc Interv; 2017 Aug 28; 10(16):1682-1690. PubMed ID: 28780030
    [Abstract] [Full Text] [Related]

  • 19. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
    Zeller T, Rastan A, Macharzina R, Tepe G, Kaspar M, Chavarria J, Beschorner U, Schwarzwälder U, Schwarz T, Noory E.
    J Endovasc Ther; 2014 Jun 28; 21(3):359-68. PubMed ID: 24915582
    [Abstract] [Full Text] [Related]

  • 20. Risk Factors for Restenosis after Drug-coated Balloon Angioplasty for Complex Femoropopliteal Arterial Occlusive Disease.
    Roh JW, Ko YG, Ahn CM, Hong SJ, Shin DH, Kim JS, Kim BK, Choi D, Hong MK, Jang Y.
    Ann Vasc Surg; 2019 Feb 28; 55():45-54. PubMed ID: 30118857
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.